Cellectis (NASDAQ:CLLS) Shares Cross Below 50-Day Moving Average - Time to Sell?

Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.43 and traded as low as $1.41. Cellectis shares last traded at $1.44, with a volume of 69,672 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLLS. Barclays lowered their target price on shares of Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen downgraded shares of Cellectis from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Cellectis Trading Down 2.0%

The company has a 50 day simple moving average of $1.43 and a 200 day simple moving average of $1.55. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $81.15 million, a PE ratio of -1.12 and a beta of 3.11.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $12.03 million during the quarter, compared to analyst estimates of $12.71 million. Analysts predict that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares during the period. OLD Mission Capital LLC purchased a new position in Cellectis during the first quarter worth about $31,000. Acadian Asset Management LLC raised its holdings in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares in the last quarter. Millennium Management LLC acquired a new stake in Cellectis in the fourth quarter valued at about $962,000. Finally, B Group Inc. acquired a new stake in Cellectis in the fourth quarter valued at about $5,547,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.